(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 August 2023 (10.08.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/150284 A3

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61P 35/00* (2006.01)
C07D 519/00 (2006.01)

(21) International Application Number:
PCT/US2023/012299

(22) International Filing Date:
03 February 2023 (03.02.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/306,271	03 February 2022 (03.02.2022)	US
63/327,625	05 April 2022 (05.04.2022)	US
63/352,180	14 June 2022 (14.06.2022)	US
63/432,243	13 December 2022 (13.12.2022)	US
63/434,327	21 December 2022 (21.12.2022)	US
63/442,648	01 February 2023 (01.02.2023)	US

(71) Applicant: **MIRATI THERAPEUTICS, INC.** [US/US]; 3545 Cray Court, San Diego, CA 92121 (US).

(72) Inventors: **WANG, Xiaolun**; c/o Mirati Therapeutics, Inc., 3545 Cray Court, San Diego, CA 92121 (US). **IVETAC, Anthony**; c/o Mirati Therapeutics, Inc., 3545 Cray Court, San Diego, CA 92121 (US). **KULYK, Svitlana**; c/o Mirati Therapeutics, Inc., 3545 Cray Court, San Diego, CA 92121 (US). **LAWSON, John David**; c/o Mirati Therapeutics, Inc., 3545 Cray Court, San Diego, CA 92121 (US). **MARX, Matthew Arnold**; c/o Mirati Therapeutics, Inc., 3545 Cray Court, San Diego, CA 92121 (US). **SMITH, Christopher Ronald**; c/o Mirati Therapeutics, Inc., 3545 Cray Court, San Diego, CA 92121 (US).

(74) Agent: **POLYAKOV, Mark V.** et al.; Wood, Phillips, Katz, Clark & Mortimer, 500 West Madison Street, Suite 1130, Chicago, IL 60661 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:
14 September 2023 (14.09.2023)

WO 2023/150284 A3

(54) Title: QUINAZOLINE PAN-KRAS INHIBITORS

(57) Abstract: The present invention relates to compounds that inhibit at least one of KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.